Mir Alikhan, MD
Hematology & Oncology · Sterling, ILNPI 1225127863
Payments from drug & device makers
Across 91 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$296
- Incyte Corporation$217
- E.r. Squibb & Sons, L.L.C.$214
- AstraZeneca$199
- Genentech USA, Inc.$120
- Novartis$110
- plus $725 from 20 others
What the payments were for
- Food & beverage$1,43876%
- Education$44324%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 20 | $296 |
| Incyte Corporation | 3 | $217 |
| E.r. Squibb & Sons, L.L.C. | 7 | $214 |
| AstraZeneca | 8 | $199 |
| Genentech USA, Inc. | 6 | $120 |
| Novartis | 5 | $110 |
| Pfizer | 5 | $100 |
| Johnson & Johnson | 6 | $86 |
| Seagen Inc. | 2 | $57 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $55 |
| Sanofi | 4 | $54 |
| Amgen | 3 | $50 |
| Eisai Inc. | 3 | $45 |
| AbbVie | 1 | $32 |
| Gilead(2 entities) | 2 | $30 |
| Astellas Pharma US Inc | 2 | $27 |
| Genmab U.S., Inc. | 1 | $25 |
| Array Biopharma Inc | 2 | $25 |
| EMD Serono, Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $21 |
| G1 Therapeutics, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$1,880 in reported general payments places this provider in the 35th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 35 | $757,810 |
| KisqaliRibociclib Succinate | 34 | $503,036 |
| RevlimidLenalidomide | 28 | $471,784 |
| JakafiRuxolitinib Phosphate | 25 | $449,233 |
| XtandiEnzalutamide | 33 | $410,958 |
| AlecensaAlectinib Hcl | 12 | $232,018 |
| ImbruvicaIbrutinib | 12 | $227,718 |
| SprycelDasatinib | 12 | $215,449 |
| CalquenceAcalabrutinib Maleate | 12 | $187,908 |
| Lenalidomide | 15 | $171,269 |
| EliquisApixaban | 250 | $165,439 |
| VenclextaVenetoclax | 11 | $107,376 |
| Imatinib Mesylate | 23 | $59,615 |
| Abiraterone Acetate | 34 | $56,104 |
| XareltoRivaroxaban | 14 | $16,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $214 | $973,25947 claims |
| NovartisKisqali | $110 | $503,03634 claims |
| Bristol Myers SquibbRevlimid | $15 | $471,78428 claims |
| Incyte CorporationJakafi | $217 | $449,23325 claims |
| Astellas Pharma US IncXtandi | $27 | $410,95833 claims |
| Genentech USA, Inc.Alecensa | $120 | $232,01812 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $55 | $227,71812 claims |
| AstraZenecaCalquence | $199 | $187,90812 claims |
| PfizerEliquis | $100 | $165,439250 claims |
| AbbVieVenclexta | $32 | $107,37611 claims |
| Johnson & JohnsonXarelto | $86 | $16,57114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Sterling
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
- Reem KarmaliChicago$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.